TY - JOUR
T1 - NIR-II fluorescence imaging-guided colorectal cancer surgery targeting CEACAM5 by a nanobody
AU - Guo, Xiaoyong
AU - Li, Changjian
AU - Jia, Xiaohua
AU - Qu, Yawei
AU - Li, Miaomiao
AU - Cao, Caiguang
AU - zhang, Zeyu
AU - Qu, Qiaojun
AU - Luo, Shuangling
AU - Tang, Jianqiang
AU - Liu, Haifeng
AU - Hu, Zhenhua
AU - Tian, Jie
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2023/3
Y1 - 2023/3
N2 - Background: Surgery is the cornerstone of colorectal cancer (CRC) treatment, yet complete removal of the tumour remains a challenge. The second near-infrared window (NIR-II, 1000–1700 nm) fluorescent molecular imaging is a novel technique, which has broad application prospects in tumour surgical navigation. We aimed to evaluate the ability of CEACAM5-targeted probe for CRC recognition and the value of NIR-II imaging-guided CRC resection. Methods: We constructed the probe 2D5-IRDye800CW by conjugated anti-CEACAM5 nanobody (2D5) with near-infrared fluorescent dye IRDye800CW. The performance and benefits of 2D5-IRDye800CW at NIR-II were confirmed by imaging experiments in mouse vascular and capillary phantom. Then mouse colorectal cancer subcutaneous tumour model (n = 15), orthotopic model (n = 15), and peritoneal metastasis model (n = 10) were constructed to investigate biodistribution of probe and imaging differences between NIR-I and NIR-II in vivo, and then tumour resection was guided by NIR-II fluorescence. Fresh human colorectal cancer specimens were incubated with 2D5-IRDye800CW to verify its specific targeting ability. Findings: 2D5-IRDye800CW had an NIR-II fluorescence signal extending to 1600 nm and bound specifically to CEACAM5 with an affinity of 2.29 nM. In vivo imaging, 2D5-IRDye800CW accumulated rapidly in tumour (15 min) and could specifically identify orthotopic colorectal cancer and peritoneal metastases. All tumours were resected under NIR-II fluorescence guidance, even smaller than 2 mm tumours were detected, and NIR-II had a higher tumour-to-background ratio than NIR-I (2.55 ± 0.38, 1.94 ± 0.20, respectively). 2D5-IRDye800CW could precisely identify CEACAM5-positive human colorectal cancer tissue. Interpretation: 2D5-IRDye800CW combined with NIR-II fluorescence has translational potential as an aid to improve R0 surgery of colorectal cancer. Fundings: This study was supported by Beijing Natural Science Foundation (JQ19027), the National Key Research and Development Program of China ( 2017YFA0205200), National Natural Science Foundation of China ( NSFC) ( 61971442, 62027901, 81930053, 92059207, 81227901, 82102236), Beijing Natural Science Foundation ( L222054), CAS Youth Interdisciplinary Team ( JCTD-2021-08), the Strategic Priority Research Program of the Chinese Academy of Sciences ( XDA16021200), the Zhuhai High-level Health Personnel Team Project (Zhuhai HLHPTP201703), the Fundamental Research Funds for the Central Universities ( JKF-YG-22-B005) and Capital Clinical Characteristic Application Research ( Z181100001718178). The authors would like to acknowledge the instrumental and technical support of the multi-modal biomedical imaging experimental platform, Institute of Automation, Chinese Academy of Sciences.
AB - Background: Surgery is the cornerstone of colorectal cancer (CRC) treatment, yet complete removal of the tumour remains a challenge. The second near-infrared window (NIR-II, 1000–1700 nm) fluorescent molecular imaging is a novel technique, which has broad application prospects in tumour surgical navigation. We aimed to evaluate the ability of CEACAM5-targeted probe for CRC recognition and the value of NIR-II imaging-guided CRC resection. Methods: We constructed the probe 2D5-IRDye800CW by conjugated anti-CEACAM5 nanobody (2D5) with near-infrared fluorescent dye IRDye800CW. The performance and benefits of 2D5-IRDye800CW at NIR-II were confirmed by imaging experiments in mouse vascular and capillary phantom. Then mouse colorectal cancer subcutaneous tumour model (n = 15), orthotopic model (n = 15), and peritoneal metastasis model (n = 10) were constructed to investigate biodistribution of probe and imaging differences between NIR-I and NIR-II in vivo, and then tumour resection was guided by NIR-II fluorescence. Fresh human colorectal cancer specimens were incubated with 2D5-IRDye800CW to verify its specific targeting ability. Findings: 2D5-IRDye800CW had an NIR-II fluorescence signal extending to 1600 nm and bound specifically to CEACAM5 with an affinity of 2.29 nM. In vivo imaging, 2D5-IRDye800CW accumulated rapidly in tumour (15 min) and could specifically identify orthotopic colorectal cancer and peritoneal metastases. All tumours were resected under NIR-II fluorescence guidance, even smaller than 2 mm tumours were detected, and NIR-II had a higher tumour-to-background ratio than NIR-I (2.55 ± 0.38, 1.94 ± 0.20, respectively). 2D5-IRDye800CW could precisely identify CEACAM5-positive human colorectal cancer tissue. Interpretation: 2D5-IRDye800CW combined with NIR-II fluorescence has translational potential as an aid to improve R0 surgery of colorectal cancer. Fundings: This study was supported by Beijing Natural Science Foundation (JQ19027), the National Key Research and Development Program of China ( 2017YFA0205200), National Natural Science Foundation of China ( NSFC) ( 61971442, 62027901, 81930053, 92059207, 81227901, 82102236), Beijing Natural Science Foundation ( L222054), CAS Youth Interdisciplinary Team ( JCTD-2021-08), the Strategic Priority Research Program of the Chinese Academy of Sciences ( XDA16021200), the Zhuhai High-level Health Personnel Team Project (Zhuhai HLHPTP201703), the Fundamental Research Funds for the Central Universities ( JKF-YG-22-B005) and Capital Clinical Characteristic Application Research ( Z181100001718178). The authors would like to acknowledge the instrumental and technical support of the multi-modal biomedical imaging experimental platform, Institute of Automation, Chinese Academy of Sciences.
KW - CEACAM5
KW - Colorectal cancer
KW - Molecular imaging
KW - Nanobody
KW - Second near-infrared window
UR - https://www.scopus.com/pages/publications/85148363206
U2 - 10.1016/j.ebiom.2023.104476
DO - 10.1016/j.ebiom.2023.104476
M3 - 文章
C2 - 36801616
AN - SCOPUS:85148363206
SN - 2352-3964
VL - 89
JO - eBioMedicine
JF - eBioMedicine
M1 - 104476
ER -